Omeros Corporation
Seattle, United States · Biotechnology, E Commerce, Email
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Seattle, United States
- Employees
- 51
- Industries
- Biotechnology, E Commerce, Email
- Status
- Public (OMER)
- Website
- www.omeros.com
- Company page
Recent activity at Omeros Corporation
- : SEC 8-K (5.02): On October 28, 2026, Omeros Corporation's Compensation Committee granted a performance-based stock option award to Gregory A. Demopulos, M.D., the company's Chief Executive Officer. The award allows for the purchase of up to 500,000 shares of the company's common stock, vesting contingent upon both stock-price performance and continued service. The award is structured to vest in four tranches based on specific stock price hurdles ($25.00, $30.00, $35.00, and $40.00) and includes a total exercise price of $17.88 per share, which aligns with the grant date's closing stock price. The terms reflect Dr. Demopulos' critical role and past achievements, notably achieving FDA approval for YARTEMLEA and enhancing the company's financial position in 2025. The option will expire on October 28, 2031.
- : SEC 8-K (5.02): On August 12, 2026, Omeros Corporation's Board of Directors appointed Joseph Schocken as a new director, expanding the board to nine members. Mr. Schocken's initial term will end at the 2027 annual meeting of shareholders. He has extensive experience in finance, being the founder of Tranceka Capital and former CEO of Broadmark Realty Capital, Inc., and has been influential in economic policy as recognized for his role in the JOBS Act. Additionally, he received a stock option to purchase 30,000 shares of common stock upon his appointment, and he will be indemnified by the Company under its standard indemnification agreement. This appointment is expected to enhance the board's expertise in financial and strategic matters.
- : SEC 8-K (8.01): On July 20, 2026, Omeros Corporation completed the repurchase of approximately $14.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029, for a total purchase price of approximately $29.0 million, which included accrued and unpaid interest. This repurchase follows a previous disclosure on July 2, 2026, where the Company agreed to repurchase a portion of these Notes in privately negotiated agreements. Overall, Omeros has retired a total of $30.5 million in Notes, leaving approximately $40.3 million outstanding. This strategic move may help the Company manage its debt and reduce interest obligations in the future.
Employee benefit plans
Omeros Corporation files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Omeros Corporation: questions and answers
What does Omeros Corporation do?
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Where is Omeros Corporation headquartered?
Omeros Corporation is headquartered in Seattle, United States.
How many employees does Omeros Corporation have?
Omeros Corporation has about 51 employees.
What is the latest news on Omeros Corporation?
On Oct 30, 2026, SEC 8-K (5.02): On October 28, 2026, Omeros Corporation's Compensation Committee granted a performance-based stock option award to Gregory A. Demopulos, M.D., the company's Chief Executive Officer. The award allows for the purchase of up to 500,000 shares of the company's common stock, vesting conti
Is Omeros Corporation a public company?
Yes. Omeros Corporation is publicly traded under the ticker OMER.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy